It was reported a 14 fr x 23 cm that the dilator tip frayed (looks to be split on the distal tip).The issue was identified during procedure, not inserted into the body, never entered into the vessel.Procedure was completed with an alternative dilator from a sheath kit, no patient complication or adverse event reported.Additional information requested.
|
The following sections were updated in follow-up 1: b4, d10, g4, g7, h2, h3, h6 and h10: the device was used in treatment.One dilator from an abiomed 14f introducer kit was returned from the customer.The introducer sheath was not returned and there were no other accessories.Blood was found on and inside the dilator.Upon evaluation of the returned product, it was found the distal tip of the dilator was damaged.The damage to the tip looks like a sharp object may have carved into the tip and almost sheared off a piece of the tip.The dilator is within manufacturing specifications.No manufacturing defects were found and the reason for return cannot be confirmed.Per abiomed introducer dilator in-process and final inspection procedure: tipping - first 5 properly tipped parts, inspect 100%.Visual inspection: using 10x microscope magnification, verify tip of dilator is round.Verify tipped dilator is free of flash, splitting, cracks, or any other damages.Verify proper tip shape according to drawing.Insert a 0.037" mandrel or 0.038" guidewire into dilator hub through to tip and check if mandrel/guidewire inserts without excessive force or obstruction.Also per abiomed 14f introducer kit packaging inspection for impella, 13cm and 25cm procedure: ensure dilator tips are perfectly round and well opened.This inspection is performed 100% by qa.The instructions for use (ifu) informs the user: when assembling the sheath and dilator, care must be taken to insert the dilator tip straight through the center of the valve membrane in order to prevent inadvertent puncturing of the membrane.Never advance or withdraw guidewire or sheath when resistance is met.Determine cause by fluoroscopy and take remedial action.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|